Endoscopic treatment outcome of oesophageal gastrointestinal stromal tumours

Table 1 Demographic and clinicopathological data of 32 patients with oesophageal gastrointestinal stromal tumour, n (%)

Parameter	Variable
Age, mean ± SD (year)	57.78 ± 7.39
< 50	4 (12.5)
≥ 50	28 (87.5)
Sex
Male	18 (56.3)
Female	14 (43.8)
Localization
Upper	2 (6.3)
Middle	10 (31.3)
Lower	20 (62.5)
Tumour size (cm)	2.12 ± 1.88 (median: 1.50, range: 0.80-2.75)
Mitotic rate
Mean (per 50 HPF, ± SD)	3.34 ± 5.04
Median (per 50 HPF, range)	1.50 (1.00-4.00)
NIH risk category
High	6 (18.8)
Intermediate	2 (6.3)
Low	6 (18.8)
Very Low	18 (56.3)
Symptoms
Asymptomatic (discovered incidentally)	28 (87.5)
Abdominal pain	3 (9.4)
Obstruction	1 (3.1)
Operation time, mean (± SD), minute	52.63 ± 43.29
Hospital stay duration, mean (± SD), day	4.22 ± 2.21
Surgical resection
En bloc resection	31 (96.9)
ER0 resection	32 (100)
R0 resection	24 (75.0)
R1 resection	8 (25.0)
Tumour growth pattern
Intraluminal growth	29 (90.6)
Extraluminal growth	3 (9.4)
Complication	8 (25.0)
Hydrothorax	4 (12.5)
PEECS	5 (15.6)

Tumour size was showed as mean ± SD and Median with quartiles. NIH: The National Institutes of Health; PEECS: Post-endoscopic submucosal dissection electrocoagulation syndrome; HPF: High-power field; ER: Endoscopic resection.